Recap: Regenxbio Q4 Earnings


Shares of Regenxbio RGNX fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 72.22% over the past year to ($1.24), which missed the estimate of ($0.43).

Revenue of $21,445,000 rose by 82.23% year over year, which missed the estimate of $61,500,000.


Earnings guidance hasn't been issued by the company for now.

Regenxbio hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Mar 01, 2021

Time: 04:30 PM

ET Webcast URL:


52-week high: $50.26

52-week low: $20.03

Price action over last quarter: Up 46.54%

Company Overview

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!